Search PubMed⌕ Search

Biomedical subjects

T Nishimura

Publications and source records attributed to T Nishimura.

At least 1,243 records · Page 69Linked to original sources
PubMed1986

[Clinical studies of cefixime in pediatric field].

Pharmacokinetic and clinical studies of cefixime (CFIX) in children were done and the following results were obtained. Serum and urinary concentrations of CFIX were determined in 6 children aged 5 to 14 years given single doses of 1.5 or 6.0 mg/kg. Mean serum concentrations peaked at 4 hours after the administration of either 1.5 or 6.0 mg/kg, and respective peak values were 0.71 and 4.46 micrograms/ml. Biological half-lives for the low and the high doses were 5.28 and 4.45 hours, respectively. The 12-hours urinary recovery ranged from 7.0 to 13.8% after administration of 1.5 mg/kg, and the 8-hours urinary recovery was 18.1% after administration of 6.0 mg/kg. Therapeutic responses were recorded as excellent or good in 43 (97.7%) of the children, comprising 13 with tonsillitis and 31 with scarlet fever. The microbiological effectiveness of CFIX on identified pathogens comprising 29 strains of S. pyogenes and 2 strains of S. aureus was satisfactory as evidence by a high eradication rate of 93.5%. No clinical side effects were observed. Abnormal laboratory findings were elevation of GOT and/or GPT in 4 patients and eosinophilia in 1 patient. In conclusion, CFIX was found to be efficacious and safe for the treatment of bacterial infections in children.

Acute Disease↗
PubMed1986

[Pharmacokinetic studies on ceftazidime in neonates].

The pharmacokinetics of ceftazidime (CAZ) were investigated in neonates. The following was a summary of the results obtained. Mean peak serum levels of CAZ reached at 15 minutes after intravenous administrations at single doses of 10 mg/kg were 31.7 micrograms/ml in 1-day-old neonates and 31.4 micrograms/ml in a 13-day-old neonate. Mean serum levels at 6 hours after administrations were 8.97 micrograms/ml and 5.26 micrograms/ml in the 1-day-old and the 13-day-old, respectively. Mean half-lives of CAZ in sera were 3.29 hours in the 1-day-old and 2.24 hours in the 13-day-old. In a 4-day-old neonate, the serum level of CAZ reached a peak of 25.4 micrograms/ml at 1 hour and was 5.75 micrograms/ml at 6 hours; the half-life was 2.41 hours. Peak serum levels of CAZ reached at 15 minutes after intravenous administrations at single doses of 20 mg/kg were 46.3 micrograms/ml in a 3-day-old neonate and 80.6 micrograms/ml in a 7-day-old neonate. The serum levels at 6 hours after administration were 12.2 micrograms/ml and 10.4 micrograms/ml, in the 3-day-old and the 7-day-old, respectively. Half-lives of CAZ in sera were 3.02 hours in the 3-day-old and 2.08 hours in the 7-day-old. In 4-day-old neonates, mean serum levels were 52.5 micrograms/ml at 15 minutes and 14.6 micrograms/ml at 6 hours after administration and the half-life was 2.76 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

Bacterial Infections↗
PubMed1986

[A parallel study of CT findings and histopathology of metastatic liver tumors].

The relation between the CT findings and the histopathology of metastatic liver tumors was investigated in nine autopsy cases of liver metastases. In hypervascular and necrotic tumors, large necrotic lesions demonstrated by CT were almost consistent with the pathological findings, but small metastatic nodules were better identified on plain CT than those on contrast-enhanced CT. Postmortem CT examination of the liver obscured metastatic nodules as compared with diagnostic CT. Diffuse liver involvement of lymphoma cannot be identified on CT examination. Plain CT is considered to be useful for screening liver metastases.

Humans↗
PubMed1986

[A case of leiomyosarcoma of the urinary bladder].

A case of leiomyosarcoma of the urinary bladder in a 33-year-old female is reported. She was admitted with the complaint of gross hematuria. Cystoscopic examination showed a thumb-tip sized mass, located at the dome. CT showed a wide-based tumor at the dome (CT number was 60.2 H.U.). Segmental resection of bladder was performed, followed by radiation and chemotherapy (VCR, ACT-D, CPM and ADM). She is alive without evidence of disease 13 months after surgery. A case report and review of the literature are presented.

Adult↗
PubMed1986

[Transurethral ureteroscopic removal of ureteral calculi].

Rigid ureteroscopy was used for transurethral removal of ureteral stones. Calculi were extracted under direct vision using flexible grasping forceps or a stone basket. If the size of the stone precluded the use of these techniques, we disintegrated the stone using an electro-hydraulic lithotriptor (EHL) or ultrasonic lithotriptor (USL). Between January, 1985 and October, 1985, 35 ureteroscopic procedures were performed for removal of ureteral stones. In 27 cases (77%) the stone was removed successfully. All stones could be removed in mid and lower ureter. However, in upper ureter, the success rate was only 50%. In 8 instances, ureteroscopy failed to remove the ureteral calculus and 6 underwent percutaneous nephrolithotomy, 2 open surgery. Of the ureteral stones, 12 were removed with grasping forceps or a basket manipulation. EHL and USL were used successfully to remove calculi in 15 cases. To make smooth passage of the ureteroscope, a 6F UPJ occlusion balloon catheter was introduced into the ureter and the balloon was inflated in the intramural ureter for 24 hours preoperatively. We have found this to be a useful procedure for smooth passage of the ureteroscope. Most common complication of ureteroscopic stone removal was fever (29%). In 1 case, the ureter was penetrated by the scope. The patient was treated with an indwelling ureteral catheter for 2 weeks. After the catheter was removed, an excretory urogram demonstrated normal ureter without extravasation or obstruction. We conclude that ureteroscopic stone removal can be done safely with careful passage of the scope and careful manipulation of calculi.

Adult↗
PubMed1986

[Asymmetric septal hypertrophy of sporadic form with abnormal thallium perfusion and myocardial enzymes].

Asymmetric septal hypertrophy with abnormal thallium scintigram and elevated cardiac enzymes were observed in five patients and were studied with special reference to the clinical significance of their clinicopathological features. They were not familial cardiomyopathy patients. Two of the five patients (Cases 1 and 2) exhibited the clinical features characteristic of hypertrophic cardiomyopathy without abnormal thallium perfusion and serum cardiac enzyme levels. A right endomyocardial biopsy for Case 1 disclosed myocardial fibrosis in addition to hypertrophy and disarray of myocardial fibers. The left ventricular cavities of two other patients (Cases 4 and 5) tended to be dilated with signs of impaired systolic function and asymmetric septal hypertrophy. A regional area of reduced thickness was observed in the medial portion of the left ventricular posterior wall of Case 4. The remaining case (Case 3) exhibited left ventricular dilatation and reduced left ventricular systolic function, disproportionate hypertrophy, and had clinical signs of congestive heart failure. Necropsy disclosed massive fibrosis and diffuse disarray of myocardial fibers. Some patients with familial hypertrophic cardiomyopathy progress to exhibit clinical features of dilated cardiomyopathy in the terminal stages, and have massive fibrosis of the myocardium histologically. Thallium scintigraphic abnormalities and elevated serum levels of cardiac enzymes, especially the LDH1 isoenzyme, in patients with hypertrophic cardiomyopathy may be a meaningful indicator of such progression in its early stages. The five patients in the present study exhibited a variety of clinical and histological features which may comprise a spectrum of clinical conditions during the progression from hypertrophic cardiomyopathy to a condition like dilated cardiomyopathy, similar to that in familial patients. This progression and the factors promoting it should be studied further in the near future.

Adult↗